Favorable safety, efficacy seen for fluocinolone.

The article reports on the 12-month data from Alimera Sciences Inc.'s study on a floucinolone acetonide intravitreal insert for the treatment of diabetic macular edema. The data indicates that patients treated with low dose showed no adverse events related to intraocular pressure (IOP), while 23.5% of patients treated with high dose had IOP increases. Chief scientific officer of Alimera, Ken Green, said the insert may offer a significant safety advantage in floucinolone acetonide delivery.